Research Paper Volume 8, Issue 12 pp 3520—3534
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer
Figure 5E. Apoptosis was measured after exposure of MSCs or HepG2 cells to 0.02μM doxorubicin plus sFlt1 (1.0 ml of concentrated conditioned medium) for 48 h. *p < 0.05, vs sFlt1 plus low-dose doxorubicin group. (F) HE staining of liver sections from mice treated with saline, continuous low-dose doxorubicin, MSC.sFlt1 and MSC.sFlt1plus continuous low-dose doxorubicin, respectively. Magnification, 200×.